Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Liu who wrote (901)	5/6/2000 8:44:00 AM
From: david james	of 1298

Its really tough to compare across biotechs since each one has its own unique pipeline, but one company to look at is Vical (VICL). They have a market cap of $400 mill. Vical Inc. is developing gene-based pharmaceutical products for human therapy. The Company's patented naked DNA gene delivery technology and proprietary lipids are designed to deliver selected genes into some cells in the body. These genes have been shown in clinical trials to cause the cells to produce desired proteins that may prevent or treat infectious and malignant diseases and other disorders. Vical is developing cancer product candidates internally while developing vaccines for infectious diseases and gene-based delivery of therapeutic proteins for other disorders primarily in collaboration with corporate partners.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next